Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CHILE MENOPAUSE DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 COUNTRY SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL'S MODEL
4.3 PORTER'S FIVE FORCES MODEL
5 PIPELINE ANALYSIS FOR CHILE MENOPAUSE DRUGS MARKET
6 CHILE MENOPAUSE DRUGS MARKET, COUNTRY SUMMARY
6.1 OVERVIEW
7 CHILE MENOPAUSE DRUG TREATMENT MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 LOW AGE OF MENOPAUSE DISORDER OCCURRENCE AS COMPARED TO OTHER REGIONS
8.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN CHILE
8.1.3 RISE IN RESEARCH AND DEVELOPMENT
8.1.4 RISE IN PHYSICAL INACTIVITY AND SEDENTARY LIFESTYLE
8.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT
8.2 RESTRAINTS
8.2.1 RISE IN COST OF THE MENOPAUSE DRUGS
8.2.2 PATENT EXPIRY
8.2.3 COMPLEXITY IN MENOPAUSE
8.2.4 LACK OF AWARENESS ABOUT MENOPAUSE
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
1.3.2 PRESENCE OF A STRONG PRODUCT PIPELINE
8.4 CHALLENGES
8.4.1 ADVERSE EFFECTS OF MEDICATION
8.4.2 AVAILABILITY OF ALTERNATIVES
9 IMPACT OF COVID-19 ON CHILE MENOPAUSE DRUG TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON SUPPLY CHAIN
9.3 IMPACT ON DEMAND
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 CHILE MENOPAUSE DRUGS MARKET, BY STAGES
10.1 OVERVIEW
10.2 POSTMENOPAUSE
10.3 PERIMENOPAUSE
10.4 MENOPAUSE
11 CHILE MENOPAUSE DRUGS MARKET, BY TYPE
11.1 OVERVIEW
11.2 NON-HORMONAL THERAPY
11.2.1 MEDICATION
11.2.1.1 ANTI-DEPRESSANTS
11.2.1.2 PAROXETINE
11.2.1.3 GABAPENTIN
11.2.1.4 CLONIDINE
11.2.1.5 OSPEMIFENE
11.2.1.6 OTHERS
11.2.2 SUPPLEMENTS
11.2.2.1 HERBAL SUPPLEMENTS
11.2.2.1.1 GINSENG
11.2.2.1.2 ASHWAGANDHA
11.2.2.1.3 OTHERS
11.2.2.2 VITAMIN D
11.2.2.3 OTHERS
11.3 HORMONAL THERAPY
11.3.1 ESTROGEN
11.3.1.1 17 B- ESTRADIOL
11.3.1.2 CONJUGATED ESTROGEN
11.3.1.3 ESTRADIOL HEMIHYDRATE
11.3.1.4 ESTERIFIED ESTROGEN
11.3.1.5 ESTERIFIED ACETATE
11.3.1.6 ESTROPIPATE
11.3.1.7 OTHERS
11.3.2 COMBINES ESTROGEN & PROGESTOGEN DRUGS
11.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P)
11.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
11.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
11.3.2.4 OTHERS
11.3.3 MEDROXYPROGESTERONE ACETATE
12 CHILE MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS
12.1 OVERVIEW
12.2 VASOMOTOR SYMPTOMS
12.2.1 HORMONAL THERAPY
12.2.2 NON-HORMONAL THERAPY
12.3 ATROPHIC VAGINITIS
12.3.1 HORMONAL THERAPY
12.3.2 NON-HORMONAL THERAPY
12.4 DYSPAREUNIA
12.4.1 HORMONAL THERAPY
12.4.2 NON-HORMONAL THERAPY
12.5 OSTEOPOROSIS
12.5.1 NON-HORMONAL THERAPY
12.5.2 HORMONAL THERAPY
12.6 DEPRESSION
12.6.1 NON-HORMONAL THERAPY
12.6.2 HORMONAL THERAPY
12.7 JOINT PAIN
12.7.1 NON-HORMONAL THERAPY
12.7.2 HORMONAL THERAPY
12.8 WEIGHT GAIN
12.8.1 HORMONAL THERAPY
12.8.2 NON- HORMONAL THERAPY
12.9 OTHERS
13 CHILE MENOPAUSE DRUGS MARKET, BY DOSAGE FORM
13.1 OVERVIEW
13.2 TABLET
13.3 CREAM
13.4 PATCH/FILM
13.5 RINGS
13.6 GEL
13.7 INJECTION SHOT
13.8 SPRAY
13.9 OTHERS
14 CHILE MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 SUBCUTANEOUS
14.3.3 OTHERS
14.4 TRANSDERMAL
14.5 VAGINAL
14.6 OTHERS
15 CHILE MENOPAUSE DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 CHILE MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACY
16.3 HOSPITAL PHARMACY
16.4 ONLINE PHARMACY
17 CHILE MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: CHILE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BAYER AG
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENTS
19.3 NOVARTIS AG
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 KNOP LABORATORIES
19.5.1 COMPANY SNAPSHOT
19.5.2 PRODUCT PORTFOLIO
19.5.3 RECENT DEVELOPMENTS
19.6 SAVAL PHARMACEUTICALS
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ITF-LABOMED FARMACEUTICA LTDA.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 TECNOFARMA S.A.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 MEGALABS CHILE S.A
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 ABBVIE INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 ABBOTT (2021)
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 FRESENIUS KABI CHILE
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 GLAXO SMITH KLINE PLC(2021)
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.14 LABORATORIOS MAVER
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 NOVO NORDISK A/S
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 SYNTHON
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 2 CHILE MENOPAUSE DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 3 CHILE MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 CHILE NON–HORMONAL THERAPY IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 CHILE MEDICATION IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 CHILE SUPPLEMENTS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 CHILE HERBAL SUPPLEMENTS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 CHILE HORMONAL THERAPY IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 CHILE ESTROGEN IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 CHILE COMBINED ESTROGEN & PROGESTOGEN DRUGS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 CHILE MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, 2020-2029 (USD MILLION)
TABLE 12 CHILE VASOMOTOR SYMPTOMS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 HORMONAL THERAPY FOR THE MANAGEMENT OF VULVOVAGINAL ATROPHY
TABLE 14 CHILE ATROPHIC VAGINITIS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 CHILE DYSPAREUNIA IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 CHILE OSTEOPOROSIS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 CHILE DEPRESSION IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 CHILE JOINT PAIN IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 CHILE VASOMOTOR SYMPTOMS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 CHILE MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 21 CHILE MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 22 CHILE PARENTERAL IN MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 CHILE MENOPAUSE DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 CHILE MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION
FIGURE 2 CHILE MENOPAUSE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 CHILE MENOPAUSE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 CHILE MENOPAUSE DRUGS MARKET: REGIONAL VS COUNTRY ANALYSIS
FIGURE 5 CHILE MENOPAUSE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CHILE MENOPAUSE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CHILE MENOPAUSE DRUGS MARKET: DBMR POSITION GRID
FIGURE 8 CHILE MENOPAUSE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 CHILE MENOPAUSE DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION
FIGURE 11 RISE IN AGEING POPULATION AMONG WOMEN IN CHILE IS EXPECTED TO DRIVE CHILE MENOPAUSE DRUGS MARKET FROM 2022 TO 2029
FIGURE 12 POSTMENOPAUSE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE CHILE MENOPAUSE DRUGS MARKET FROM 2022 & 2029
FIGURE 13 REGULATORY PROCESS OF DRUGS AND BIOLOGICS APPROVAL IN CHILE
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF CHILE MENOPAUSE DRUGS MARKET
FIGURE 15 CHILE IMPORTS: MEDICINAL AND PHARMACEUTICAL PRODUCT
FIGURE 16 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, 2021
FIGURE 17 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, 2020-2029 (USD MILLION)
FIGURE 18 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 19 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 20 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, 2021
FIGURE 21 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, 2021
FIGURE 25 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, 2020-2029 (USD MILLION)
FIGURE 26 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, CAGR (2022-2029)
FIGURE 27 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, LIFELINE CURVE
FIGURE 28 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, 2021
FIGURE 29 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, 2020-2029 (USD MILLION)
FIGURE 30 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 33 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 34 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 35 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 CHILE MENOPAUSE DRUGS MARKET: BY END USER, 2021
FIGURE 37 CHILE MENOPAUSE DRUGS MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 38 CHILE MENOPAUSE DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 CHILE MENOPAUSE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 42 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 CHILE MENOPAUSE DRUGS MARKET: COMPANY SHARE 2021 (%)
